Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More

As we ring in 2025, Cancer Research Catalyst wishes you a very Happy New Year! May your 2025 be full of love, connection, and inspiration. As always, we love to keep you connected with inspiring cancer research by sharing this month’s editors’ picks from the 10 American Association for Cancer Research (AACR) journals. December’s holiday… Continue reading Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More

Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies

Abstract Designing and carrying out a controlled human infection (CHI) model for hepatitis C virus (HCV) is critical for vaccine development. However, key considerations for a CHI model protocol include understanding of the earliest viral-host kinetic events during the acute phase and susceptibility of the viral isolate under consideration for use in the CHI model… Continue reading Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies

Unprecedented Advances and Persistent Challenges: Key Insights from AACR’s 2024 Cancer Progress Reports

In 2024, the American Association for Cancer Research (AACR) released the 14th edition of the annual AACR Cancer Progress Report and the third edition of the biennial AACR Cancer Disparities Progress Report that highlight the remarkable progress made in understanding cancer’s complexities, improving early detection and treatment options, and addressing inequities in patient care. Together,… Continue reading Unprecedented Advances and Persistent Challenges: Key Insights from AACR’s 2024 Cancer Progress Reports

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data

A multivariate predictive model was constructed using baseline and 12-week clinical data to evaluate the rate of clearance of hepatitis B surface antigen (HBsAg) at the 48-week mark in patients diagnosed with … Continue reading on BioMed Central

Response Letter to the Editor

We agree with Zhang et al’s letter [1] regarding our publication [2], In fact, we discussed limitations of being a single center study (their first point) and having a limited schedule of serial blood collection (point 2) in our discussion [2]. With more frequent longitudinal blood collection, our reported surveillance sensitivity may actually increase. We… Continue reading Response Letter to the Editor